Immunocore Holdings plc (IMCR)

Market Cap	1.42B
Revenue (ttm)	296.31M
Net Income (ttm)	-47.05M
Shares Out	50.03M
EPS (ttm)	-0.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	193,102
Open	28.70
Previous Close	28.42
Day's Range	27.79 - 29.29
52-Week Range	27.69 - 76.98
Beta	0.73
Analysts	Buy
Price Target	65.18 (+130.12%)
Earnings Date	Nov 6, 2024

About IMCR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company’s product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 497
• Stock Exchange: NASDAQ
• Ticker Symbol: IMCR
• Website: https://www.immunocore.com

Financial Performance

In 2023, Immunocore Holdings's revenue was $249.43 million, an increase of 43.05% compared to the previous year's $174.36 million. Losses were -$55.29 million, 5.22% more than in 2022.

Analyst Forecast

According to 13 analysts, the average rating for IMCR stock is "Buy." The 12-month stock price forecast is $65.18, which is an increase of 130.12% from the latest price.

Price Target

$65.18

(130.12% upside)

Analyst Consensus: Buy